Accreditation
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Conexiant Education. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 17.75 contact hours. Designated contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses will be available closer to the event.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 17.75 contact hour(s) (1.775 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-25-156-L01-P)
Type of Activity: Application
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 17.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 17.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Education Credit
To be eligible for credit and to receive a certificate, participants must complete the full activity and submit a completed evaluation form. This activity will also be available in an enduring (on demand) format from November 5 through December 31, 2025. Participants may claim continuing education credit for either format by completing all required components, including the post activity evaluation. All evaluations must be submitted online by December 31, 2025.
Intended Audience
The intended audience for this conference is nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and clinicians who specialize in the field of oncology.
Learning Objectives
- Summarize recent drug approvals, including indications, mechanisms of action, and clinical trial data
- Develop evidence-based treatment plans involving sequencing therapies, managing adverse events, and providing supportive care
- Apply updated guidelines, biomarker testing, and pharmacogenomics for personalized care
- Integrate complex therapies (e.g., CAR T-cell therapy, TILs, ImmTACs) into care plans safely
- Identify communication and leadership skills for shared decision-making and patient advocacy
Conference Chair
Rose DiMarco, PharmD, BCPS, BCOP
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Planning Committee
Lisa Kottschade, APRN, MSN, CNP, FAPO
Mayo Clinic
Andrew Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
Cincinnati Cancer Advisors
Lorinda A. Coombs, PhD, CNS, FNP-BC, AOCNP®
University of North Carolina Chapel Hill School of Nursing and Lineberger Comprehensive Cancer Center
Yi (Lisa) Hwa Christenson, APRN, DNP, CNP, FAPO
Mayo Clinic
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
Cleveland Clinic
Kelly Haviland, PhD, RN, MSN, FNP-BC
Memorial Sloan Kettering Cancer Center
Amber Koehler, MPAS, PA-C
Mayo Clinic
Amy Pierre, MSN, ANP-C
Memorial Sloan Kettering Cancer Center and Flatiron Health
Beth Sandy, MSN, CRNP, FAPO
Abramson Cancer Center
Kate Taucher, PharmD, MHA, BCOP, FAPO
UCHealth Memorial Hospital
Haleigh Mistry, MS, PA-C
MD Anderson Cancer Center
Steven Wei, EdD, MPH, MS, PA-C, DFAAPA
MD Anderson Cancer Center
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
In accordance with Joint Accreditation requirements, the following individuals have disclosed relevant financial relationships with ineligible companies:
- Lisa Hwa Christenson, DNP has disclosed financial relationships with Sanofi, GSK, Janssen, Shield Therapeutics, and Pfizer.
- Lorinda Coombs, PhD, MSN, FNP-BC, AOCNP has disclosed that her spouse is an employee of Machaon and a speaker for Alexion.
- Rose DiMarco, PharmD, BCPS, BCOP has disclosed financial relationships with Gilead, Lilly, Acclinate, CE Synergy’s Peak Exchange, and Pharmacy and Healthcare Communications.
- Kelly Haviland, PhD, FNP-BC, RN, TGNB-C has disclosed a financial relationship with Johnson & Johnson.
- Amber Koehler, MPAS, PA-C has disclosed financial relationships with AbbVie, Pharmacyclics, AstraZeneca, and BMS.
- Beth Faiman, PhD, MSN has disclosed financial relationships with Bristol Myers Squibb (BMS), Sanofi, GSK, and Janssen.
- Andrew Guinigundo, MSN, RN, CNP, ANP-BC, FAPO has disclosed financial relationships with Amgen, Astellas, AstraZeneca, GlaxoSmithKline, Natera, Castle, and Pfizer.
- Beth Sandy, MSN, CRNP, FAPO has disclosed financial relationships with Merck, Takeda, Amgen, AstraZeneca, Jazz, Lilly, Pfizer, and Janssen.